Progyny, Inc.

PGNY Healthcare Healthcare Plans

Progyny, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.3 billion, up 10.4% from fiscal 2024. In the quarter to June 2026, revenue grew 5.30%, EPS grew 80.0% and free cash flow fell 12.0%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.

26.86 0.60 −2.18%
Market cap
$2.1B
P/E
27.7×
Fwd P/E
19.9×
Dividend yield
—
F-score
8/9
Altman Z
8.89
Beneish M
−3.45
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Piotroski F-Score
8 8 8 8

+8 more TTM periods

ROE
16.24% 14.93% 12.48% 11.37%
ROA
10.65% 9.48% 8.67% 7.77%
ROIC
32.40% 28.15% 25.88% 24.98%
Return on Tangible Assets
24.97% 22.45% 15.43% 12.97%
Average Days of Receivables
71.70 74.41 62.39 72.64
Free Cash Flow per Share
2.28 2.28 2.24 2.25
Free Cash Flow
178.38 184.42 191.78 193.46
Other line items

Show all line items

Columns are period end dates